NCT05919407View on ClinicalTrials.gov

Pyridostigmine and Amifampridine for Myasthenia Gravis

PHASE3UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 22, 2023

Primary Completion Date

September 22, 2024

Study Completion Date

September 22, 2024

Conditions
Myasthenia Gravis
Interventions
DRUG

Pyridostigmine

Participants will receive pyridostigmine 10 mg tablets.

DRUG

Amifampridine (base) with modified release

Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.

DRUG

Placebo

The placebo tablets will be identical apart from the active substance (pyridostigmine)

DRUG

Placebo

The placebo tablets will be identical apart from the active substance (amifampridine base)

Trial Locations (1)

2333 ZA

RECRUITING

Leiden University Medical Center, Leiden

Sponsors

Collaborators (1)

NMD Pharma A/S
All Listed Sponsors
collaborator

NMD Pharma A/S

INDUSTRY

lead

Leiden University Medical Center

OTHER

NCT05919407 - Pyridostigmine and Amifampridine for Myasthenia Gravis | Biotech Hunter | Biotech Hunter